Esperion
Manufacturing · Michigan, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
3891 Ranchero Dr Ste 150, Ann Arbor, Mic...Phone Number
(734) 887-3903Website
www.esperion.comRevenue
$418.2 MillionStock Symbol
ESPRIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
4
4
1
1
1
1
About Esperion
Esperion was founded in 2008. Since then, our teams have worked diligently to discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases. The status quo is not meeting the health needs of millions of people with high cholesterol that is why our team of passionate industry leaders is breaking through the barriers that prevent patients from reaching their goals. Providers are moving toward reducing LDL-cholesterol levels as low as possible, as soon as possible; we provide the next steps to help get patients there. Because when it comes to high cholesterol, getting to goal is not optional. It is our lifes work.Explore more
Esperion Org Chart
Get the full picture
Sign in to uncover key details.
Show More
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Esperion your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Esperion has new funding data
Esperion, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Esperion launches new products
Click to see if Esperion had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Esperion recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Esperion has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Esperion
Check out if Esperion is spiking on competitors!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Esperion
Compare insights from companies similar to Esperion, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Esperion is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Esperion is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Esperion.
Esperion financials insights
Gather financial insights about Esperion, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2010
Private Equity
$5M
2013
Other Financing Round
$33M
Stock Offering
$70M
2014
Stock Offering
$85M
2015
Stock Offering
$189.9M
2017
Stock Offering
$151.9M
2020
Debt
$200M
2021
Other Financing Round
$50M
Esperion Tech Stack
A closer look at the technologies used by Esperion
See more technologies
Most Recent Scoops
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
Open Position
Open Position
Open Position
Open Position
Esperion News & Media
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANN ARBOR, Mich., May 14, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on May 12 2026, the Company granted 23 new employees 260,000 restricted stock units (RSUs) under Esperion’s 2017 Inducement Equity Incentive Plan.Esperion Announces Two New Analyses Supporting Bempedoic Acid to Reduce LDL-C Levels to be Presented at the European Atherosclerosis Society (EAS) Congress 2026
– Presentations Examine Findings From the Pediatric Phase 2 Study, As Well As Factors Associated With Enhanced LDL-C Reductions in Adult Patients Enrolled in Clear Outcomes –Esperion agrees to $1.1 billion ARCHIMED buyout - The Globe and Mail
Detailed price information for Esperion Theraptc (ESPR-Q) from The Globe and Mail including charting and trades.ARCHIMED to acquire Esperion Therapeutics in $1.1 billion deal - Quartz
Shareholders will receive $3.16 per share in cash at closing — a 58% premium — plus contingent payments of up to $100 million
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Esperion
Sign Up For FreeTo access detailed company insights
Esperion was founded in 2008. Since then, our teams have worked diligently to discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases. The status quo is not meeting the health needs of millions of people with high cholesterol that is why our team... Read More
